Efficient elimination of MELAS-associated m.3243G mutant mitochondrial DNA by an engineered mitoARCUS nuclease

Nuclease-mediated editing of heteroplasmic mitochondrial DNA (mtDNA) seeks to preferentially cleave and eliminate mutant mtDNA, leaving wild-type genomes to repopulate the cell and shift mtDNA heteroplasmy. Various technologies are available, but many suffer from limitations based on size and/or specificity. The use of ARCUS nucleases, derived from naturally occurring I-CreI, avoids these pitfalls due to their small size, single-component protein structure and high specificity resulting from a robust protein-engineering process. Here we describe the development of a mitochondrial-targeted ARCUS (mitoARCUS) nuclease designed to target one of the most common pathogenic mtDNA mutations, m.3243A>G. mitoARCUS robustly eliminated mutant mtDNA without cutting wild-type mtDNA, allowing for shifts in heteroplasmy and concomitant improvements in mitochondrial protein steady-state levels and respiration. In vivo efficacy was demonstrated using a m.3243A>G xenograft mouse model with mitoARCUS delivered systemically by adeno-associated virus. Together, these data support the development of mitoARCUS as an in vivo gene-editing therapeutic for m.3243A>G-associated diseases.

Automated summary

This study developed a mitochondrial-targeted nuclease called mitoARCUS to target the common pathogenic mtDNA mutation m.3243A>G. mitoARCUS efficiently eliminated mutant mtDNA without affecting wild-type mtDNA, leading to improvements in mitochondrial protein steady-state levels and respiration. In vivo experiments using an adeno-associated virus delivery system in a m.3243A>G xenograft mouse model demonstrated the efficacy of mitoARCUS. These findings support the development of mitoARCUS as a gene-editing therapeutic for m.3243A>G-associated diseases.